• 1. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Organooxygen compounds
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds

Introduction to 1-Hexanamine, 6-(aminooxy)-, dihydrochloride (CAS No. 139376-42-4)

1-Hexanamine, 6-(aminooxy)-, dihydrochloride, identified by its Chemical Abstracts Service (CAS) number 139376-42-4, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioconjugation. This compound belongs to a class of molecules characterized by the presence of both amino and aminooxy functional groups, making it a versatile intermediate in the synthesis of various bioactive molecules. The dihydrochloride salt form enhances its solubility in aqueous systems, facilitating its application in solution-phase reactions and biomedical formulations.

The structure of 1-Hexanamine, 6-(aminooxy)-, dihydrochloride consists of a hexyl chain with an amino group at one end and an aminooxy group at the sixth carbon position. This unique arrangement imparts distinct chemical properties that make it valuable in drug design and molecular recognition. The aminooxy group, specifically, is known for its ability to participate in nucleophilic addition reactions and form stable oxime linkages, which are crucial in the development of prodrugs and enzyme inhibitors.

In recent years, research has highlighted the potential of 1-Hexanamine, 6-(aminooxy)-, dihydrochloride as a building block in the synthesis of targeted therapeutics. Its bifunctional nature allows for the facile attachment of pharmacophores or biomolecules via either the primary amino group or the aminooxy moiety. This feature has been exploited in the development of conjugates for site-specific delivery systems, such as antibody-drug conjugates (ADCs) and peptidomimetics. The ability to precisely modify the molecular architecture of these conjugates enhances their therapeutic efficacy while minimizing off-target effects.

One of the most compelling applications of 1-Hexanamine, 6-(aminooxy)-, dihydrochloride is in the field of proteolysis-targeting chimeras (PROTACs). These novel molecular entities leverage the power of protein degradation to eliminate pathogenic proteins from cells. The compound’s ability to form stable linkages with both ligands and target proteins makes it an ideal candidate for designing PROTACs that can selectively induce proteasomal degradation of specific disease-causing proteins. Preliminary studies have demonstrated promising results in targeting proteins associated with cancer and neurodegenerative disorders.

The pharmaceutical industry has also explored 1-Hexanamine, 6-(aminooxy)-, dihydrochloride as a precursor in the synthesis of kinase inhibitors. Kinases are enzymes that play critical roles in cell signaling pathways, and their dysregulation is often associated with various diseases, particularly cancer. By incorporating this compound into drug candidates, researchers aim to develop inhibitors that can selectively modulate kinase activity without affecting other cellular processes. The dihydrochloride salt form ensures high purity and stability, which are essential for pharmaceutical-grade intermediates.

Advances in synthetic methodologies have further expanded the utility of 1-Hexanamine, 6-(aminooxy)-, dihydrochloride. Modern techniques such as transition-metal-catalyzed cross-coupling reactions and enzymatic biocatalysis have enabled more efficient and scalable production processes. These innovations not only improve yield but also reduce costs, making it more feasible to incorporate this compound into large-scale drug manufacturing. Additionally, green chemistry principles have been applied to minimize waste and hazardous byproducts during synthesis.

The bioconjugation capabilities of 1-Hexanamine, 6-(aminooxy)-, dihydrochloride extend beyond small molecule drugs to include nucleic acid therapeutics. Ongoing research is exploring its use in antisense oligonucleotides (ASOs) and RNA interference (RNAi) agents. These therapies target specific mRNA sequences to modulate gene expression, offering potential treatments for genetic disorders and infectious diseases. The compound’s ability to link nucleic acids with other therapeutic moieties could enhance delivery efficiency and stability.

In conclusion,1-Hexanamine, 6-(aminooxy)-, dihydrochloride (CAS No. 139376-42-4) represents a significant advancement in medicinal chemistry due to its multifunctional nature and broad applicability. Its role as a key intermediate in drug development continues to evolve with emerging research findings. As scientists uncover new ways to leverage its unique properties,1-Hexanamine, 6-(aminooxy)-, dihydrochloride is poised to play an increasingly pivotal role in addressing unmet medical needs across various therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)